The US Healthcare Affordability Crisis: What Rising Costs Mean for Americans in 2026
American healthcare in 2026 is defined by a painful paradox: medical innovation has never been more impressive, yet the cost of accessing that innovation has never been more crushing. From the expiration of enhanced Affordable Care Act subsidies to double-digit medical trend rates, from hospital consolidation to pharmacy benefit manager opacity, the affordability crisis is reshaping how Americans experience — or fail to experience — healthcare.
The Subsidy Cliff and Its Aftermath
The most immediate shock to healthcare affordability came on January 1, 2026, when enhanced Premium Tax Credits (EPTCs) — the expanded ACA subsidies that had kept marketplace insurance affordable for millions of Americans — expired. Despite last-minute legislative efforts by both Democrats and Republicans in late 2025, no bipartisan deal emerged, and premium costs spiked for an estimated 20 million Americans who had relied on the enhanced subsidies.
The Kaiser Family Foundation had warned that without the EPTCs, premium payments would increase substantially, with some enrollees facing premium increases of hundreds of dollars per month. The actual impact has been severe: enrollment data from early 2026 suggests a significant decline in marketplace coverage, with lower-income enrollees disproportionately affected. For many families, the choice has become stark — pay dramatically higher premiums, switch to bare-bones plans with massive deductibles, or go uninsured entirely.
The Rockefeller Institute of Government has flagged this as one of the defining healthcare trends of 2026, noting that “consumers will more directly feel the cost of healthcare” as the subsidy cliff combines with broader inflationary pressures on medical services, prescription drugs, and hospital care.
The Employer Squeeze
For the roughly 160 million Americans who receive health insurance through employers, 2026 has brought its own affordability challenges. Employer health plan costs are projected to rise by 7-8% in 2026, continuing a multi-year trend of increases that consistently outpace both inflation and wage growth. Aon’s Global Medical Trend Rates Report and Mercer Marsh Benefits’ Health Trends 2026 report both confirm double-digit medical trend rates across most global markets, with the United States among the hardest hit.
Employers are responding with a mix of strategies that increasingly shift costs to workers. Higher deductibles, narrower networks, increased premium contributions, and the elimination of underperforming vendor partners are all on the table. The Business Group on Health’s 2026 Employer Health Care Strategy Survey found that employers face “heightened urgency and a willingness to pursue approaches that more effectively disrupt their benefits program,” including potentially “pursuing fundamentally different arrangements with key partners, especially in the areas linked to high-cost drivers.”
The practical impact on workers is substantial. The average family health insurance premium has crossed $25,000 annually, with workers’ share averaging more than $7,000. Combined with deductibles that routinely exceed $3,000 for individual coverage, many insured Americans are functionally underinsured — technically covered but unable to afford the out-of-pocket costs required to actually use their insurance.
Hospital Consolidation and the Price Problem
A major driver of healthcare costs that has intensified in 2026 is hospital and health system consolidation. The federal Department of Health and Human Services released a comprehensive report documenting how consolidation in healthcare markets leads to higher prices without corresponding improvements in quality. When hospital systems merge, the resulting market power enables them to negotiate higher reimbursement rates from insurers, costs that are ultimately passed through to consumers in the form of higher premiums.
The American Hospital Association has pushed back, arguing that consolidation is necessary for struggling rural and community hospitals to survive. Their April 2025 report documented that “hospitals and health systems are squeezed by persistent economic challenges,” including workforce shortages, rising supply costs, and inadequate reimbursement from government payers. But the empirical evidence on consolidation’s price effects is clear: markets with higher hospital concentration have significantly higher prices, and those higher prices are borne by patients, employers, and taxpayers.
Pharmacy Costs: The Black Box Problem
Prescription drug spending continues to be one of the fastest-growing components of healthcare costs, driven by specialty drugs, biologics, and the explosive growth of GLP-1 medications. While the Inflation Reduction Act’s drug price negotiation provisions have begun to exert modest downward pressure on Medicare drug spending, the broader pharmacy cost ecosystem remains deeply opaque.
Pharmacy benefit managers — the intermediaries that negotiate drug prices on behalf of insurers and employers — operate with minimal transparency, and their business models often create perverse incentives. Spread pricing (charging payers more than they reimburse pharmacies and keeping the difference), rebate retention, and formulary placement fees generate significant revenue for PBMs but obscure the true cost of medications and often leave patients paying more at the pharmacy counter than they would in a transparent market.
Congressional scrutiny of PBM practices has intensified, but comprehensive reform legislation has stalled amid industry lobbying. The result is a system where the list price of a drug, the negotiated price, the patient’s out-of-pocket cost, and the net price after rebates bear little relationship to one another — a black box that frustrates patients, employers, and policymakers alike.
Medical Debt: The Human Cost
Behind the statistics and policy debates are millions of Americans whose lives have been derailed by medical debt. An estimated 100 million Americans carry some form of medical debt, making it the leading cause of bankruptcy in the United States. Even among the insured, high deductibles and surprise billing can generate crushing financial obligations from a single emergency room visit or unexpected diagnosis.
The Consumer Financial Protection Bureau has proposed rules to remove medical debt from credit reports, recognizing that medical debt is a poor predictor of creditworthiness and that its presence on credit reports creates a cycle of financial harm — limiting access to housing, employment, and credit — that compounds the original health crisis. But rulemaking has been slow, and millions of Americans continue to see their financial futures compromised by the simple misfortune of getting sick.
What Could Actually Help
Addressing the healthcare affordability crisis requires moving beyond ideological debates about public versus private insurance to focus on the structural factors that drive costs regardless of who writes the check. Meaningful solutions include site-neutral payment policies that prevent hospital-owned facilities from charging higher prices than independent providers for identical services, aggressive antitrust enforcement against healthcare consolidation, PBM transparency and reform legislation, and the extension of drug price negotiation beyond Medicare to the commercial market.
The expiration of enhanced ACA subsidies has demonstrated that affordability is not a static achievement but an ongoing policy commitment. Restoring those subsidies — or better yet, making them permanent — would provide immediate relief to millions. But the deeper challenge is bending the cost curve itself, a task that requires confronting powerful entrenched interests across the healthcare industry. In 2026, the affordability crisis is visible everywhere — in skipped medications, deferred care, medical debt collections, and the quiet desperation of families choosing between healthcare and other necessities. The question is whether the political will to address it will match the scale of the problem.
